Effect of age on pulmonary metastases and immunotherapy in young and middle-aged mice

Yuh Min Chen, Pi Sheng Wang, Jacqueline Ming Liu, Yi Lin Hsieh, Chun Ming Tsai, Reury Perng Perng, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: We used B16-F1O (B16) melanoma tumor cells and syngeneic C57BL/6 (B6) mice as a study model for pulmonary metastases, to better understand whether or not there exist differences in tumorigenicity and in the effectiveness of immunotherapy as a function of host age (1-, 3-, 12- and 24-month-old). Methods: Intravenous injection of B16 melanoma cells were administered to B6 mice of different ages with/without interleukin (IL)-2 and IL-12 daily treatment. Tumor growth, splenocyte function, serum cytokines (IL-10, interferon-γ, vascular endothelial growth factor) and survival were compared. Results: The study showed that, without IL-2 and IL-12 treatment, middle-aged mice suffering from pulmonary metastases had fewer pulmonary metastases and better survival than younger mice suffering from pulmonary metastases. Three days' IL-2 plus IL-12 treatment could not prolong mice survival, but prolonged treatment significantly improved the survival of both the younger and older tumor-bearing mice, especially the older mice, despite the fact that the younger mice had a better serum cytokine and splenocyte cellular immune response to cytokine treatment. Conclusion: The young B6 mice that suffered from B16 pulmonary metastases had a poorer prognosis than the middle-aged mice. Short-term IL-2 plus IL-12 treatment is ineffective in prolonging survival, and a longer duration of treatment is needed. This kind of immunotherapy was effective in both the young and middle-aged mice, but it was more effective in the middle-aged mice.

Original languageEnglish
Pages (from-to)94-102
Number of pages9
JournalJournal of the Chinese Medical Association
Volume70
Issue number3
DOIs
Publication statusPublished - Jan 1 2007
Externally publishedYes

Fingerprint

Immunotherapy
Neoplasm Metastasis
Lung
Interleukin-12
Interleukin-2
Experimental Melanomas
Cytokines
Therapeutics
Neoplasms
Serum
Psychological Stress
Cellular Immunity
Intravenous Injections
Interleukin-10
Interferons
Vascular Endothelial Growth Factor A

Keywords

  • Age
  • Immunotherapy
  • Pulmonary metastases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of age on pulmonary metastases and immunotherapy in young and middle-aged mice. / Chen, Yuh Min; Wang, Pi Sheng; Liu, Jacqueline Ming; Hsieh, Yi Lin; Tsai, Chun Ming; Perng, Reury Perng; Whang-Peng, Jacqueline.

In: Journal of the Chinese Medical Association, Vol. 70, No. 3, 01.01.2007, p. 94-102.

Research output: Contribution to journalArticle

Chen, Yuh Min ; Wang, Pi Sheng ; Liu, Jacqueline Ming ; Hsieh, Yi Lin ; Tsai, Chun Ming ; Perng, Reury Perng ; Whang-Peng, Jacqueline. / Effect of age on pulmonary metastases and immunotherapy in young and middle-aged mice. In: Journal of the Chinese Medical Association. 2007 ; Vol. 70, No. 3. pp. 94-102.
@article{62e202b7baa24dd3a2f32625a60bb2a5,
title = "Effect of age on pulmonary metastases and immunotherapy in young and middle-aged mice",
abstract = "Background: We used B16-F1O (B16) melanoma tumor cells and syngeneic C57BL/6 (B6) mice as a study model for pulmonary metastases, to better understand whether or not there exist differences in tumorigenicity and in the effectiveness of immunotherapy as a function of host age (1-, 3-, 12- and 24-month-old). Methods: Intravenous injection of B16 melanoma cells were administered to B6 mice of different ages with/without interleukin (IL)-2 and IL-12 daily treatment. Tumor growth, splenocyte function, serum cytokines (IL-10, interferon-γ, vascular endothelial growth factor) and survival were compared. Results: The study showed that, without IL-2 and IL-12 treatment, middle-aged mice suffering from pulmonary metastases had fewer pulmonary metastases and better survival than younger mice suffering from pulmonary metastases. Three days' IL-2 plus IL-12 treatment could not prolong mice survival, but prolonged treatment significantly improved the survival of both the younger and older tumor-bearing mice, especially the older mice, despite the fact that the younger mice had a better serum cytokine and splenocyte cellular immune response to cytokine treatment. Conclusion: The young B6 mice that suffered from B16 pulmonary metastases had a poorer prognosis than the middle-aged mice. Short-term IL-2 plus IL-12 treatment is ineffective in prolonging survival, and a longer duration of treatment is needed. This kind of immunotherapy was effective in both the young and middle-aged mice, but it was more effective in the middle-aged mice.",
keywords = "Age, Immunotherapy, Pulmonary metastases",
author = "Chen, {Yuh Min} and Wang, {Pi Sheng} and Liu, {Jacqueline Ming} and Hsieh, {Yi Lin} and Tsai, {Chun Ming} and Perng, {Reury Perng} and Jacqueline Whang-Peng",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/S1726-4901(09)70338-7",
language = "English",
volume = "70",
pages = "94--102",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Effect of age on pulmonary metastases and immunotherapy in young and middle-aged mice

AU - Chen, Yuh Min

AU - Wang, Pi Sheng

AU - Liu, Jacqueline Ming

AU - Hsieh, Yi Lin

AU - Tsai, Chun Ming

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: We used B16-F1O (B16) melanoma tumor cells and syngeneic C57BL/6 (B6) mice as a study model for pulmonary metastases, to better understand whether or not there exist differences in tumorigenicity and in the effectiveness of immunotherapy as a function of host age (1-, 3-, 12- and 24-month-old). Methods: Intravenous injection of B16 melanoma cells were administered to B6 mice of different ages with/without interleukin (IL)-2 and IL-12 daily treatment. Tumor growth, splenocyte function, serum cytokines (IL-10, interferon-γ, vascular endothelial growth factor) and survival were compared. Results: The study showed that, without IL-2 and IL-12 treatment, middle-aged mice suffering from pulmonary metastases had fewer pulmonary metastases and better survival than younger mice suffering from pulmonary metastases. Three days' IL-2 plus IL-12 treatment could not prolong mice survival, but prolonged treatment significantly improved the survival of both the younger and older tumor-bearing mice, especially the older mice, despite the fact that the younger mice had a better serum cytokine and splenocyte cellular immune response to cytokine treatment. Conclusion: The young B6 mice that suffered from B16 pulmonary metastases had a poorer prognosis than the middle-aged mice. Short-term IL-2 plus IL-12 treatment is ineffective in prolonging survival, and a longer duration of treatment is needed. This kind of immunotherapy was effective in both the young and middle-aged mice, but it was more effective in the middle-aged mice.

AB - Background: We used B16-F1O (B16) melanoma tumor cells and syngeneic C57BL/6 (B6) mice as a study model for pulmonary metastases, to better understand whether or not there exist differences in tumorigenicity and in the effectiveness of immunotherapy as a function of host age (1-, 3-, 12- and 24-month-old). Methods: Intravenous injection of B16 melanoma cells were administered to B6 mice of different ages with/without interleukin (IL)-2 and IL-12 daily treatment. Tumor growth, splenocyte function, serum cytokines (IL-10, interferon-γ, vascular endothelial growth factor) and survival were compared. Results: The study showed that, without IL-2 and IL-12 treatment, middle-aged mice suffering from pulmonary metastases had fewer pulmonary metastases and better survival than younger mice suffering from pulmonary metastases. Three days' IL-2 plus IL-12 treatment could not prolong mice survival, but prolonged treatment significantly improved the survival of both the younger and older tumor-bearing mice, especially the older mice, despite the fact that the younger mice had a better serum cytokine and splenocyte cellular immune response to cytokine treatment. Conclusion: The young B6 mice that suffered from B16 pulmonary metastases had a poorer prognosis than the middle-aged mice. Short-term IL-2 plus IL-12 treatment is ineffective in prolonging survival, and a longer duration of treatment is needed. This kind of immunotherapy was effective in both the young and middle-aged mice, but it was more effective in the middle-aged mice.

KW - Age

KW - Immunotherapy

KW - Pulmonary metastases

UR - http://www.scopus.com/inward/record.url?scp=34247382458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247382458&partnerID=8YFLogxK

U2 - 10.1016/S1726-4901(09)70338-7

DO - 10.1016/S1726-4901(09)70338-7

M3 - Article

C2 - 17389153

AN - SCOPUS:34247382458

VL - 70

SP - 94

EP - 102

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 3

ER -